Biomarker discovery plays a crucial role in immunotherapy, particularly in predicting treatment responses. Key findings reveal the effectiveness of nivolumab and durvalumab across various disease stages, while highlighting the limited role of PD-L1 in small cell lung cancer. The significance of CD8 positive cells and KRAS mutations is discussed, along with the importance of adapting treatments based on CTDNA responses and the timing of immunotherapy administration.